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Abstract
Aims Endothelial activation and inflammatory cell infiltration have important roles in the development of cardiac fibrosis
induced by renin–angiotensin system activation. NADPH oxidases (Nox proteins) are expressed in endothelial cells (ECs) and
alter their function. Previous studies indicated that Nox2 in ECs contributes to angiotensin II (AngII)-induced cardiac fibrosis.
However, the effects of EC Nox4 on cardiac fibrosis are unknown.
Methods and results Transgenic (TG) mice overexpressing endothelial-restricted Nox4 were studied alongside wild-type
(WT) littermates as controls. At baseline, Nox4 TG mice had significantly enlarged hearts compared with WT, with elongated
cardiomyocytes (increased by 18.5%, P < 0.01) and eccentric hypertrophy but well-preserved cardiac function by echocardi-
ography and in vivo pressure–volume analysis. Animals were subjected to a chronic AngII infusion (AngII, 1.1 mg/kg/day) for
14 days. Whereas WT/AngII developed a 2.1-fold increase in interstitial cardiac fibrosis as compared with WT/saline controls
(P < 0.01), TG/AngII mice developed significant less fibrosis (1.4-fold increase, P > 0.05), but there were no differences in
cardiac hypertrophy or contractile function between the two groups. TG hearts displayed significantly decreased inflammatory
cell infiltration with reduced levels of vascular cell adhesion molecule 1 in both the vasculature and myocardium compared
with WT after AngII treatment. TG microvascular ECs stimulated with AngII in vitro supported significantly less leukocyte
adhesion than WT ECs.
Conclusions A chronic increase in endothelial Nox4 stimulates physiological cardiac hypertrophy and protects against
AngII-induced cardiac fibrosis by inhibiting EC activation and the recruitment of inflammatory cells.
Highlights
• Mice with endothelium-specific overexpression of Nox4 (EndoNox4 TG) exhibit eccentric hypertrophy with well-preserved
cardiac function at baseline.
• EndoNox4 TG mice develop significantly less interstitial cardiac fibrosis in response to chronic pressure AngII stimulation,
independent of cardiac hypertrophy.
• Overexpression of Nox4 in endothelial cells reduces AngII-induced endothelial activation.
• An increase in endothelial Nox4 inhibits AngII-induced recruitment of inflammatory cells in the heart.
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Introduction
Myocardial fibrosis involving the excessive deposition of
extracellular matrix and accumulation of abnormally
cross-linked collagen alters both the geometry and mechani-
cal properties of the heart over time and constitutes an im-
portant component of adverse cardiac remodelling.1 The
extent of myocardial fibrosis is associated with higher mortal-
ity in patients with heart failure. However, current treatment
regimens are ineffective in reducing or reversing fibrosis,2
largely because the fundamental mechanisms underlying
the fibrotic progression remain incompletely understood.
Activation of endothelial cells (ECs), in particular via in-
creased expression of adhesion receptors such as vascular
cell adhesion molecule 1 (VCAM-1) that recruit circulating
inflammatory cells and the localized secretion of cytokines,3
is involved in cardiac fibrosis. Increased activation of the re-
nin–angiotensin–aldosterone system (RAAS) plays a central
role in pro-inflammatory and pro-fibrotic actions and modu-
lating endothelial function. Growing evidence indicates that
these effects are strongly regulated through redox-sensitive
processes, particularly the activation of NADPH oxidases
(Nox), which are major sources of reactive oxygen species
(ROS) in cardiovascular system.4
Of the seven Nox isoforms (Nox1–5, Duox1–2) that have
been identified so far, Nox2 and Nox4 are the most abun-
dantly expressed in the heart. Previous studies found that
Nox2 is involved in the pathophysiology of angiotensin II
(AngII)-dependent endothelial dysfunction and the develop-
ment of cardiac fibrosis. Interstitial fibrosis induced by
activation of the renin–angiotensin system was inhibited
in Nox2 knockout mice or in cardiomyocyte-specific Rac1
knockout mice (which have deficient Nox2 activation).5–7
The finding that deletion of Nox2 may attenuate fibrosis
without altering the extent of cardiomyocyte hypertrophy
suggested that the effects of Nox2 may involve a cell type
extrinsic to myocytes.6,8 Indeed, our studies revealed that
endothelial Nox2 contributes to AngII-induced cardiac
fibrosis through pro-inflammatory effect via induction
of VCAM-1 and increased endothelial–mesenchymal
transition.8
In contrast to Nox2, Nox4 is constitutively active and is reg-
ulated mainly by its level of abundance.9 Using global Nox4
knockout mice and cardiomyocyte-specific transgenic (TG)
mouse models, our previous studies showed that Nox4 is pro-
tective against cardiac hypertrophy, contractile dysfunction,
and fibrosis in response to pressure overload or myocardial
ischaemia. Different cardiomyocyte-based adaptive mecha-
nisms may be involved including a paracrine preservation of
myocardial capillary density,10 Nrf2-dependent modulation
of redox state,11 and enhancement of the integrated stress
response.12 Nox4 is highly expressed in the endothelium,13
but the role of endothelial Nox4 in cardiac fibrosis and re-
modelling has not been investigated.
In this study, we employed a previously generated TG
mouse model with endothelial-targeted overexpression of
Nox4 (EndoNox4 TG)14 to evaluate the effects of endothelial
Nox4 on AngII-induced cardiac fibrosis.
Material and methods
Animal studies
All procedures were performed in accordance with the
Guidance on the Operation of the Animals (Scientific Proce-
dures) Act, 1986 (UK Home Office). Endothelium-targeted
Nox4 overexpression (EndoNox4 TG) using an established
tie2 promoter construct was described previously.14 Mice
were backcrossed onto a C57BL/6 background for>10 gener-
ations. We studied male mice aged 8–16 weeks and matched
wild-type (WT) littermates.
Angiotensin II (1.1 mg/kg/day) or saline vehicle was
infused via subcutaneously implanted osmotic minipumps
(Model 1002, Alzet, Cupertino, CA) for 14 days. Echocardiog-
raphy was performed under 2% isoflurane anaesthesia with
heart rates maintained >400 b.p.m. using a Vevo 2100
machine with a 30 MHz linear array transducer (Visualsonics,
Toronto, CA).15 Left ventricular (LV) pressure–volume (PV)
relations were measured with a 1.4F microconductance
catheter system (SPR-839, Millar Instruments, Houston, TX)
introduced retrogradely into the LV via the right carotid
artery under 2% isoflurane anaesthesia.8
Assessment of isolated cardiomyocyte size
Fresh ventricular myocytes were isolated from mouse hearts
as described.15 Isolated cardiomyocytes suspended in me-
dium were analysed in a Coulter counter-analyser system
(Multisizer 3 Coulter Counter, Beckman Coulter, Inc., USA)
to measure the cell volume. Cardiomyocytes were also plated
on slides, and images were obtained under light microscopy
(Zeiss Axioscope, Germany) to evaluate cell length.16
Immunoblotting, histology, and
immunohistochemistry
Proteins were extracted and Western blots performed using
standard procedures. Cardiomyocyte area and cardiac fibrosis
were quantified in 6 μm paraffin LV sections stained with
wheat-germ agglutinin (WGA) and Picrosirius Red,
respectively.10 Collagen content was calculated as % of total
LV area. Capillaries were stained with isolectin B4 (Vector
B-1205), and capillary density was quantified as the number
of capillaries per square millimetre.10 Immunostaining was
performed using primary antibodies and HRP-labelled
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secondary antibodies, with visualization by diaminobenzidine
(DAKO kit SK4100, Vector Laboratories). CD45-positive,
CD3-positive, or Mac3-positive cells were counted using
semi-automated software (AxioVision v4.6, Carl Zeiss,
Germany) and expressed as average counts over 10 fields.
The following antibodies were used: anti-VCAM-1 (AF643,
R&D Systems), anti-β-actin (ab8227, Abcam), anti-CD45
(550539, BD Biosciences), anti-Mac3 (550292, BD Biosci-
ences), and anti-CD3 (ab5690, Abcam).
Real-time PCR
mRNA expression levels were quantified by real-time RT–PCR
using SYBR Green on an Applied Biosystems PRISM 7700
machine. Data were analysed using the comparative Ct
method and normalized by β-actin levels. Primer sequences
were (forward, reverse): Anf, atrial natriuretic factor:
ATTGGAGCCCACAGTGGACTA, CCTTTTCCTCCTTGGCTGTTATC;
P1np, type I procollagen: CCTCAGGGTATTGCTGGACAAC,
TTGATCCAGAAGGACCTTGTTTG; P3np, type III
procollagen: AGGAGCCAGTGGCCATAATG, TGACCATCTGA
TCCAGGGTTTC; Fn, fibronectin: CCGGTGGCTGTCAGTCAGA,
CCGTTCCCACTGCTGATTTATC; Tnf-α, tumour necrosis factor
α: GTTCTATGGCCCAGACCCTCA, TCCACTTGGTGGTTTGCTACG;
Il-6, interleukin-6: GAAAAGAGTTGTGCAATGGCAAT, TTGGTA
GCATCCATCATTTCTTTG.
En face immunofluorescence staining
The expression levels of VCAM-1 were assessed in ECs at
regions of the lesser curvature [low shear (LS) site], greater
curvature [high shear (HS) site], and descending mouse aor-
tae by en face staining as described previously.17 Briefly,
mice were treated with AngII (1.1 mg/kg/day) or saline
for 48 h before killing by CO2 inhalation. Mice were slowly
perfused with cold phosphate-buffered saline and then
perfusion-fixed with 2% formalin before harvesting. Aortae
were cut longitudinally along the greater curvature to re-
veal the endothelial surface and tested by immunostaining
using primary antibody against VCAM-1 or isotype IgG as
a negative control and Alexa Fluor 568-conjugated second-
ary antibodies (red). ECs were identified by co-staining
using anti-CD31 antibody (CBL1337, Chemicon) conjugated
to the fluorophore FITC, and nuclei were co-stained using
Draq5 (BioStatus). Fluorescence images were taken using
confocal laser scanning microscopy (Zeiss LSM 510 META,
Germany). The expression of VCAM-1 was assessed by
quantification of fluorescence intensity of four random im-
ages of each site using Velocity software in a blinded
manner.
Leukocyte adhesion flow assay
Coronary microvascular endothelial cells (CMECs) were
isolated from hearts of 6- to 8-week-old mice and used at
Passages 2–3.8 Interaction between CMECs and leukocytes
was measured by flow assay as reported previously.8 Briefly,
a parallel plate flow chamber (GlycoTech, Maryland) was as-
sembled with confluent CMEC monolayers, which had been
previously incubated with or without AngII (100 nmol/L) for
4 h. Bone marrow cells were isolated from WT mice and la-
belled with CellTracker dye (Invitrogen) prior to perfusion
over stimulated CMEC monolayers at a cell density of
1 × 106 cells/mL and a shear stress of 2.5 dyn/cm2 for
30 min. The first 10 min of perfusion was with bone marrow
cell suspension, and the subsequent 20 min was without
cells. Non-bound leukocytes were eventually cleared with
continued perfusion of media lacking cells. The remaining
adherent cells were visualized using an inverted time-lapse
fluorescence microscope (Olympus IX81). The number of
recruited leukocytes was counted in 8–10 fields of view per
flow assay performed on four separate occasions.
Statistics
Data are presented as mean ± SEM. Comparisons between TG
and WT were made by unpaired Student’s t-test for two
groups. Two-way ANOVA was used to compare treatment
responses between TG and WT followed by Bonferroni
post-tests. Analyses were performed on GraphPad Prism
(8.0.0 for Windows, San Diego, CA). P < 0.05 was considered
statistically significant.
Results
EndoNox4 transgenic mice exhibit eccentric
cardiac hypertrophy at baseline
EndoNox4 TG mice showed no obvious abnormalities at base-
line and bred normally, as described previously.14 We first
examined the effect of endothelial-specific Nox4 overexpres-
sion on basal cardiac morphology and function. EndoNox4 TG
mice exhibited enlarged hearts in terms of higher LV weight/
body weight ratio (Figure 1A). Echocardiography revealed
that EndoNox4 TG mouse hearts had significantly increased
intraventricular septal thickness in diastole (IVSD) compared
with WT littermates (Figure 1B). However, LV relative wall
thickness (RWT), defined as the ratio of IVSD plus posterior
LV wall thickness to the LV internal diameter at end-diastole
(LVEDD), was similar in TG and WT hearts18 (Figure 1C). This
finding suggested an eccentric pattern of hypertrophy in TG
hearts, a phenotype similar to physiological cardiac
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hypertrophy. The cardiomyocyte cross-sectional area in heart
sections indicated that the myocyte width was not signifi-
cantly different between TG and WT (Figure 1D). The length
of isolated cardiomyocytes, however, was significantly
increased by 18% in TG mice (Figure 1E). Consistent with
these data, the average volume of cardiomyocytes was signif-
icantly greater in TG mice compared with WT (Figure 1F).
There was no difference in myocardial capillary density
between the genotypes (Figure 1G).
We next evaluated the cardiac functional consequences of
the eccentric hypertrophy. Echocardiographic fractional
shortening (FS) was similar in EndoNox4 TG and WT hearts
(Figure 1H). Cardiac contractility was further assessed by in
vivo pressure–volume analysis. TG mice displayed slightly
Figure 1 EndoNox4 TG mice exhibit physiological cardiac hypertrophy. (A) Left ventricle/body weight ratios (LV/BW). n = 10 mice/group. (B–C) Cardiac
hypertrophy evaluated by echocardiography. IVSD, interventricular septum thickness at end-diastole. Relative wall thickness: (IVSD + post wall diam-
eter)/LVEDD as indicator of concentric hypertrophy. n = 8 mice/group. (D) Quantification of transverse heart cross-sectional area for cardiomyocyte
width determination. n = 6 hearts/group. (E) Quantification of isolated cardiomyocyte length. n = 4 hearts/group. (F) Mean data of cell volumes
assessed on a Coulter counter. n = 4 hearts/group. (G) Mean data for capillary density. n = 4 hearts/group. (H–J) Cardiac systolic function measured
by echo and PV loop analysis. n = 5 mice/group. Ees, end-systolic elastance; PRSW, preload recruitable stroke work. (K–L) Cardiac diastolic function
evaluated by PV loop analysis. EDPVR, end-diastolic pressure–volume relationship. n = 5 mice/group. *P < 0.05, **P < 0.01, compared with WT mice,
unpaired Student’s t-test. All data are mean ± SEM.
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increased indices of LV systolic function as evidenced by
significantly higher preload recruitable stroke work (PRSW)
(Figure 1I) but with an unaltered end-systolic elastance
(Ees) (Figure 1J). Both the isovolumic relaxation time con-
stant, τ, and the LV end-diastolic pressure volume relation-
ship (EDPVR) were similar between EndoNox4 TG and WT
mice (Figure 1K and 1L).
Taken together, these results indicate that EndoNox4 TG
mice exhibit baseline eccentric hypertrophy with a physiolog-
ical pattern of slightly enhanced LV systolic function and no
impairment of diastolic function.
EndoNox4 transgenic and wild-type mice develop
similar extent of cardiac hypertrophy in response
to angiotensin II
EndoNox4 TG and WT littermates were subjected to chronic
AngII infusion for 2 weeks (1.1 mg/kg/day). Echocardio-
graphic evaluation showed that EndoNox4 TG had a larger
LV end-diastolic dimension (LVEDD) and cardiac output than
WT mice both before and after AngII infusion, with no effect
of AngII itself (Figure 2A and 2B). This is consistent with the
baseline phenotype of eccentric cardiac hypertrophy in TG
mice. Similarly, AngII infusion did not significantly change
the LV end-systolic dimension (LVESD) in either group (data
not shown), and overall cardiac function as assessed by FS
was also unchanged (Figure 2C). Cardiac hypertrophy as
assessed by the IVSD was induced by AngII in both WT and
TG mice, but the magnitude of increase was similar between
genotypes (Figure 2D). However, the RWT only increased in
WT mice treated with AngII, consistent with a pattern of con-
centric hypertrophy, but remained unaltered in TG/AngII
mice (Figure 2E). The results for cardiac hypertrophy were
confirmed by the measurement of LV weight/body weight ra-
tio and showed a similar increase in AngII-treated WT and TG
mice (Figure 2F). Similarly, at a cellular level, cardiomyocyte
hypertrophy as assessed by cross-sectional area increased
to an equivalent extent in WT and TG hearts (Figure 2G).
We also quantified changes in the myocardial mRNA levels
of Anf, which typically increases with pathological hypertro-
phy. There was no difference in mRNA expression of Anf
between EndoNox4 TG and WT at baseline, while after AngII
infusion the levels increased to a similar extent in both
groups (Figure 2H). These data indicate that while an increase
in endothelial Nox4 induces baseline eccentric hypertrophy,
the hypertrophic response to chronic AngII stimulation is
similar between genotypes.
Endothelial Nox4 protects against angiotensin
II-induced myocardial fibrosis
Myocardial fibrosis was assessed in LV sections stained with
Picrosirius Red. The level of fibrosis was very low in both
saline-treated WT and TG mouse hearts, suggesting that an
increased level of Nox4 in ECs does not have significant
effects on the extracellular matrix at baseline (Figure 3A
and 3B). Two-week AngII infusion significantly enhanced
myocardial fibrosis by 2.1-fold in WT hearts. However, this
increase was markedly blunted (to around 1.4-fold) in TG
mouse hearts after AngII treatment (Figure 3A and 3B). At a
molecular level, AngII markedly increased the gene expres-
sion of the pro-fibrotic genes P1np and P3np in WT mouse
hearts, but this was significantly blunted in TG/AngII mice
(Figure 3C and 3D). The mRNA levels of fibronectin increased
to a similar extent in both WT and TG hearts (Figure 3E).
These data suggest that endothelial Nox4 is protective
against AngII-induced myocardial fibrosis.
Endothelial Nox4 reduces angiotensin II-induced
inflammatory cell infiltration in the heart
To investigate mechanisms underlying the attenuated fibrosis
in EndoNox4 TG hearts, we assessed myocardial inflammatory
cell infiltration, which is known to contribute to AngII-induced
cardiac fibrosis.8 As expected, AngII treatment significantly
increased CD45 (pan-leukocyte marker)-positive and CD3
(T-cell marker)-positive cells in WT hearts (Figure 4A–4C). TG
hearts, however, had significantly less CD45+ inflammatory
cells and CD3+ cells after AngII infusion thanWT hearts (Figure
4A–4C). The numbers of Mac3 (macrophage marker)-positive
cells were elevated to a similar extent in both WT and TG
hearts after AngII infusion (Figure 4D). AngII treatment
also significantly increased the mRNA levels of several
pro-inflammatory cytokines including tumour necrosis factor
α (Tnf-α) (Figure 4E) and interleukin 6 (Il-6) (Figure 4F) in WT
hearts. However, these increases were virtually abolished in
TG mice infused with AngII (Figure 4E and 4F).
Nox4 attenuates endothelial activation by
inhibition of vascular cell adhesion molecule 1
expression
To further investigate the interrelationship between endo-
thelial Nox4 and inflammatory cells, we first quantified the
protein levels of VCAM-1, an important endothelial-
expressed cell adhesion molecule involved in the recruitment
of leukocytes. While there was no difference between geno-
types after saline infusion, the increase in VCAM-1 levels after
chronic AngII infusion was significantly lower in TG hearts
compared with WT (Figure 5A).
To assess the effects of in vivo AngII infusion specifically on
the endothelial levels of VCAM-1 at an early stage, we
employed en face staining of the aorta after 2 days of
treatment with AngII or saline. Three regions of aorta were
evaluated: LS region, HS region of aortic arch, and descending
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ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13228
aorta. The levels of basal VCAM-1 were very low in all aortic
regions with no difference between WT and TG mice in
saline-treated groups. AngII stimulated an increase in
VCAM-1 levels, especially in the HS region of the WT aortic
arch (Figure 5B). In mice with endothelial-specific overexpres-
sion of Nox4, the AngII-induced up-regulation of VCAM-1 was
Figure 2 EndoNox4 TG mice develop similar extent of cardiac hypertrophy as WT in response to AngII stimulation. (A–C) Cardiac function assessed by
echocardiography. LVEDD, left ventricular end-diastolic dimension. n = 8 mice/group. (D–E) Echocardiographic measurement of interventricular sep-
tum thickness at end-diastole (IVSD) and relative wall thickness. n = 8 mice/group. (F) LV weight and body weight ratios. n = 10 mice/group. (G) Rep-
resentative transverse heart sections for cardiomyocyte area determination stained with WGA. Scale bars: 20 μm. Mean data shown on the right. n = 6





P < 0.01 compared with respective WT mice; two-way ANOVA with post-Bonferroni tests. All data are mean ± SEM.
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markedly attenuated in the HS region (Figure 5B). Similar
trends were observed in the LS region and descending aorta
but did not reach significance (Figure 5B).
Finally, we assessed the functional interaction between
inflammatory cells and Nox4-overexpressing ECs in an
in vitro adhesion assay under flow conditions. Leukocyte
Figure 3 Overexpression of endothelial Nox4 attenuates AngII-induced myocardial fibrosis. (A) Representative images of myocardial interstitial fibrosis
by Picrosirius Red staining. Scale bar: 100 μm. (B) Quantification of myocardial fibrosis. n = 8 hearts/group. (C–E) Quantification of mRNA levels of
fibrotic markers. n = 8 hearts/group. *P < 0.05, **P < 0.01 compared with respective saline groups; two-way ANOVA with post-Bonferroni tests.
All data are mean ± SEM.
Figure 4 Overexpression of endothelial Nox4 alleviates AngII-induced inflammatory cell infiltration in the heart. (A) Typical immunostaining images of
CD45 inflammatory cells. Scale bar: 25 μm. Arrows indicate CD45-positive cells shown as brown colour and counter-stained with Harris solution. (B–D)
Quantifications of CD45-positive, CD3-positive, and Mac3-positive cells. n = 8 hearts/group. (E–F) mRNA levels of pro-inflammation genes tumour ne-




P < 0.01 compared with WT/AngII; two-way ANOVA with post-Bonferroni tests. All data are mean ± SEM.
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attachment to either WT or TG CMECs was low at baseline.
After AngII treatment (100 nmol/L, 4 h), however, there was
a significant increase in the number of leukocytes attached
to WT CMECs (Figure 6). This AngII-induced increase was
completely inhibited when CMECs from EndoNox4 TG mouse
heart were used in the assay (Figure 6). These findings sug-
gest that endothelial Nox4 inhibits activation of EC and their
interaction with leukocytes in the heart.
Discussion
In this study, we found that an elevation of Nox4 levels in the
endothelium significantly reduces the development of
AngII-induced myocardial fibrosis without affecting the ex-
tent of cardiac hypertrophy. Investigation of the underlying
mechanisms revealed that endothelial Nox4 decreases
VCAM-1 expression in both the vasculature and myocardium
and therefore reduces endothelial–leukocyte interaction. As
a result, endothelial Nox4 protects against AngII-induced
myocardial inflammation and fibrosis. We also found that a
constitutive increase in endothelial Nox4 is associated with
modest eccentric cardiac hypertrophy with physiological
characteristics, that is, preserved systolic and diastolic con-
tractile function.
The heathy endothelium is considered to be a
gatekeeper of cardiovascular homeostasis by maintaining
anti-inflammatory and anti-thrombotic states.19 ECs can be
activated by various pathologic stimuli, such as increased re-
nin–angiotensin system activation or cytokine signalling.
Activated ECs express pro-inflammatory cell surface adhesion
molecules such as VCAM-1 and secrete pro-inflammatory
molecules such as TNF-α and IL-6, which act in concert to
promote leukocyte adhesion and recruitment and perpetuate
tissue inflammation.20 In the heart, sustained activation of
ECs and associated pro-inflammatory effects may enhance
cardiac fibrosis and remodelling. Previous studies suggested
that endothelial Nox-derived ROS modulate VCAM-1-depen-
dent lymphocyte migration.21 The importance of endothelial
Nox2 in endothelial activation in response to chronic AngII
stimulation was later demonstrated in a TG mouse model
with EC-targeted Nox2 overexpression.8,22 EC Nox2 increased
the number of inflammatory cells in the heart at least in part
through an enhanced expression of VCAM-1.8 In the current
study, we find that mice with EC-specific overexpression of
Nox4 manifest opposite effects to those of Nox2, with a sig-
nificant decrease in AngII-stimulated VCAM-1 expression in
vessels and myocardium. This inhibition of VCAM-1 expres-
sion was associated with reduced endothelial–leukocyte
adhesion in an in vitro flow assay, as well as less inflammatory
cell infiltration in the heart in vivo after AngII treatment.
These results indicate that, in contrast to Nox2, an increase
in Nox4 in ECs has a beneficial effect against AngII-induced
cardiac inflammation and fibrosis, at least in part by inhibiting
endothelial activation. The mechanism whereby Nox4 down-
regulates VCAM-1 was not addressed in the current study.
However, it has previously been reported that endothelial
activation is inhibited by the induction of the transcription
factor Nrf2, which plays a critical role in the maintenance of
endothelial homeostasis and resistance to AngII and
cytokine-induced injury.23,24 Importantly, Nox4 is an essential
Figure 5 Forced expression of Nox4 in endothelial cells decreases VCAM-1 expression by AngII stimulation. (A) Protein levels of VCAM-1 in the heart
by Western blot. Mean data shown at the below. n = 4 hearts/group. (B) Representative en face staining of VCAM-1 in aortic greater curvature site
[high shear (HS) region]. Green: CD31 staining for endothelial cells. Red: VCAM-1 staining. Purple: Draq5 staining for nuclei. Mean data of fluorescence
density of VCAM-1 shown at the right. LS, low stress region. n = 4 vessels/group. *P< 0.05, **P< 0.01 compared with WT/saline.
#
P< 0.05 compared
with WT/AngII; two-way ANOVA with post-Bonferroni tests. All data are mean ± SEM.
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modulator of Nrf2 activation in the vasculature13 and myo-
cardium, both physiologically25 and in disease settings such
as pressure overload.11
Reactive oxygen species play complex cell-specific and
context-specific roles in pathophysiological processes such as
cardiac remodelling. Considerable evidence implicates
Nox2-derived ROS in the development of cardiac remodelling,
including interstitial fibrosis.5 While a reduction in AngII-
induced cardiac fibrosis was first identified in global Nox2
knockout mice, subsequent studies have shown that several
different cell types play a role.6,26 Evidence obtained with
TG mice overexpressing Nox2 in ECs indicated a prominent
contribution of endothelial Nox2 to AngII-dependent cardiac
fibrosis.8 A recent study showed that Nox2 in regulatory T
cells may also act to enhance AngII-induced cardiac fibrosis.27
Although a detrimental effect of Nox2 is supported by
numerous studies, the role of Nox4 is unclear. Some studies
showed that Nox4 in fibroblasts promoted cardiac fibrosis in
response to RAAS activation28,29 or TGF-β stimulation.30 It
was reported that a high level of cardiomyocyte-specific
Nox4 overexpression, with eight-fold greater ROS produc-
tion, exaggerated AngII-induced cardiac hypertrophy and
fibrosis.31 However, it is argued that excessively high levels
of Nox4 are likely to result in non-physiological effects.32
Our previous studies using both global Nox4KO and
cardiomyocyte-specific overexpressing mice demonstrated
that cardiomyocyte Nox4 is protective against adverse re-
modelling in response to pressure overload and myocardial
infarction.10–12,33,34 Here, we show that mice overexpressing
Nox4 in ECs develop significantly less AngII-induced myocar-
dial fibrosis without affecting AngII-induced cardiomyocyte
hypertrophy. Moreover, endothelial Nox4 was also found
Figure 6 Endothelial Nox4 inhibits AngII-induced endothelial activation. (A) Typical images of leukocytes binding to coronary microvascular endothelial
cells (CMECs). Top panels: phase images; bottom panels: fluorescence images in which green spots indicate leukocytes adhered to underlying endo-
thelial cells. (B) Quantification of bone marrow-isolated leukocytes binding to CMECs after 30 min of continuous flow, expressed in the ratio of number
of adhesive inflammatory cells towards number of endothelial cells in the same view. n = 4. *P< 0.05, compared with WT/saline.
##
P< 0.01 compared
with WT/AngII; two-way ANOVA with post-Bonferroni tests. All data are mean ± SEM.
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to be protective against interstitial fibrosis in the pressure-
overloaded heart.35
Interestingly, we also found a baseline state of modest
physiological cardiac hypertrophy in EndoNox4 TG mice. This
TG model has a 2.6-fold increase in endothelial Nox4 protein
levels and two-fold more H2O2 production than WT, without
changes in Nox2 and subunit p22phox expressions.14 We
found that EndoNox4 TG mice displayed modestly enlarged
hearts and an increased IVSD, with a pattern of eccentric
hypertrophy similar to physiological cardiac hypertrophy.
Consistent with a physiological hypertrophic response,
EndoNox4 TG mice had well-preserved systolic function, by
both echocardiography and PV loop analysis, as well as
normal diastolic function. Molecular markers of pathological
hypertrophy, that is, Anf, were unaltered in the EndoNox4
Tg heart. It has long been recognized that cardiac ECs may
influence both cardiomyocyte contractile state36,37 and car-
diac growth, the latter especially during development.38,39
The mechanisms underlying Nox4-dependent physiological
cardiomyocyte growth were not investigated in the present
study, but there are a number of possibilities. It was reported
that H2O2, the preferential product of Nox4, could release
neuregulin 1 from ECs to exert hypertrophic effects on
cardiomyocytes.40,41 In addition, Nox4 activates eNOS to pro-
mote nitric oxide (NO) production,13 which could chronically
increase coronary blood flow and induce cardiomyocyte
growth.42 High NO levels from ECs may also promote nearby
cardiomyocyte hypertrophy by favouring the degradation of
regulator 4 of G-protein signalling.43 Altogether, the presence
of physiological cardiac hypertrophy in EndoNox4 TG mice at
baseline suggests that ROS-dependent crosstalk between ECs
and cardiomyocytes may influence cardiac growth.
The development of myocardial fibrosis is an important
component in the progression of cardiac remodelling to heart
failure. ECs play important roles in fibrosis and remodelling
through interactions with other cell types, in particular
inflammatory cells. This study shows that the up-regulation
of endothelial Nox4 can act to abrogate EC activation and
pathological inflammation. The results also indicate
complex and distinct roles of Nox2 and Nox4 in modulating
fibrosis. Based on the current data, approaches to target
Nox-derived ROS need to be isoform specific.
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